GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diva Laboratories Ltd (ROCO:4153) » Definitions » Piotroski F-Score

Diva Laboratories (ROCO:4153) Piotroski F-Score : 5 (As of Jun. 09, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Diva Laboratories Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Diva Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Diva Laboratories's Piotroski F-Score or its related term are showing as below:

ROCO:4153' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Diva Laboratories was 8. The lowest was 2. And the median was 5.


Diva Laboratories Piotroski F-Score Historical Data

The historical data trend for Diva Laboratories's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diva Laboratories Piotroski F-Score Chart

Diva Laboratories Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 3.00 4.00 4.00 7.00

Diva Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 6.00 8.00 5.00

Competitive Comparison of Diva Laboratories's Piotroski F-Score

For the Diagnostics & Research subindustry, Diva Laboratories's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diva Laboratories's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Diva Laboratories's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Diva Laboratories's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Dec22) TTM:
Net Income was 21.418 + 11.743 + 19.421 + 24.371 = NT$77.0 Mil.
Cash Flow from Operations was 21.699 + 152.035 + 1.162 + 47.226 = NT$222.1 Mil.
Revenue was 248.795 + 232.938 + 207.249 + 222.388 = NT$911.4 Mil.
Gross Profit was 74.841 + 67.108 + 61.493 + 62.515 = NT$266.0 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Mar24) was
(1251.798 + 1237.56 + 1268.956 + 1223.63 + 1293.692) / 5 = NT$1255.1272 Mil.
Total Assets at the begining of this year (Dec22) was NT$1,251.8 Mil.
Long-Term Debt & Capital Lease Obligation was NT$4.3 Mil.
Total Current Assets was NT$1,012.5 Mil.
Total Current Liabilities was NT$303.4 Mil.
Net Income was 1.858 + 3.485 + 22.626 + 21.692 = NT$49.7 Mil.

Revenue was 192.914 + 224.766 + 236.203 + 295.321 = NT$949.2 Mil.
Gross Profit was 39.884 + 56.861 + 68.884 + 100.502 = NT$266.1 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1181.689 + 1171.092 + 1176.748 + 1177.399 + 1251.798) / 5 = NT$1191.7452 Mil.
Total Assets at the begining of last year (Dec21) was NT$1,181.7 Mil.
Long-Term Debt & Capital Lease Obligation was NT$0.2 Mil.
Total Current Assets was NT$976.4 Mil.
Total Current Liabilities was NT$234.6 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Diva Laboratories's current Net Income (TTM) was 77.0. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Diva Laboratories's current Cash Flow from Operations (TTM) was 222.1. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=76.953/1251.798
=0.06147398

ROA (Last Year)=Net Income/Total Assets (Dec21)
=49.661/1181.689
=0.04202544

Diva Laboratories's return on assets of this year was 0.06147398. Diva Laboratories's return on assets of last year was 0.04202544. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Diva Laboratories's current Net Income (TTM) was 77.0. Diva Laboratories's current Cash Flow from Operations (TTM) was 222.1. ==> 222.1 > 77.0 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Mar24
=4.343/1255.1272
=0.00346021

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=0.153/1191.7452
=0.00012838

Diva Laboratories's gearing of this year was 0.00346021. Diva Laboratories's gearing of last year was 0.00012838. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=1012.465/303.362
=3.33748129

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=976.386/234.591
=4.16207783

Diva Laboratories's current ratio of this year was 3.33748129. Diva Laboratories's current ratio of last year was 4.16207783. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Diva Laboratories's number of shares in issue this year was 58.903. Diva Laboratories's number of shares in issue last year was 58.895. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=265.957/911.37
=0.2918211

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=266.131/949.204
=0.28037282

Diva Laboratories's gross margin of this year was 0.2918211. Diva Laboratories's gross margin of last year was 0.28037282. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=911.37/1251.798
=0.72804877

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=949.204/1181.689
=0.80326042

Diva Laboratories's asset turnover of this year was 0.72804877. Diva Laboratories's asset turnover of last year was 0.80326042. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+0+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Diva Laboratories has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Diva Laboratories  (ROCO:4153) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Diva Laboratories Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Diva Laboratories's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Diva Laboratories (ROCO:4153) Business Description

Traded in Other Exchanges
N/A
Address
9F, No. 351 Sector 2, Chung Shan Road, Chung Ho, New Taipei City, TWN, 235
Diva Laboratories Ltd is a Taiwan-based company that engages in the manufacturing and sale of a medical display. It offers endo/surgical displays; color displays for radiology and medical imaging services; touch displays; and original design manufacturing and original equipment manufacturing solutions.

Diva Laboratories (ROCO:4153) Headlines

No Headlines